These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 3472242

  • 1. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ.
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [Abstract] [Full Text] [Related]

  • 2. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO, Calves MJ, Natoli EJ.
    J Immunol; 1987 Mar 01; 138(5):1524-9. PubMed ID: 3805726
    [Abstract] [Full Text] [Related]

  • 3. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ.
    Proc Natl Acad Sci U S A; 1995 Mar 28; 92(7):2805-9. PubMed ID: 7708728
    [Abstract] [Full Text] [Related]

  • 4. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [Abstract] [Full Text] [Related]

  • 5. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO.
    Cancer Res; 1995 Jul 01; 55(13):2783-8. PubMed ID: 7796403
    [Abstract] [Full Text] [Related]

  • 6. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO.
    Immunol Rev; 1995 Jun 01; 145():147-66. PubMed ID: 7590824
    [Abstract] [Full Text] [Related]

  • 7. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
    Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, Old LJ.
    Proc Natl Acad Sci U S A; 1990 May 01; 87(9):3333-7. PubMed ID: 2159145
    [Abstract] [Full Text] [Related]

  • 8. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO.
    Int J Cancer; 2000 Mar 01; 85(5):659-66. PubMed ID: 10699946
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of melanoma-associated gangliosides in cancer patients.
    Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL.
    Int J Cancer; 1985 May 15; 35(5):607-12. PubMed ID: 3997282
    [Abstract] [Full Text] [Related]

  • 10. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni.
    Ritter G, Fortunato SR, Cohen L, Noguchi Y, Bernard EM, Stockert E, Old LJ.
    Int J Cancer; 1996 Apr 10; 66(2):184-90. PubMed ID: 8603809
    [Abstract] [Full Text] [Related]

  • 11. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
    Livingston PO, Ritter G, Calves MJ.
    Cancer Immunol Immunother; 1989 Apr 10; 29(3):179-84. PubMed ID: 2731184
    [Abstract] [Full Text] [Related]

  • 12. Ganglioside vaccines with emphasis on GM2.
    Livingston P.
    Semin Oncol; 1998 Dec 10; 25(6):636-45. PubMed ID: 9865678
    [Abstract] [Full Text] [Related]

  • 13. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
    Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G.
    J Clin Oncol; 1994 May 10; 12(5):1036-44. PubMed ID: 8164027
    [Abstract] [Full Text] [Related]

  • 14. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
    Livingston P, Zhang S, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M.
    Cancer Immunol Immunother; 1997 Jan 10; 43(6):324-30. PubMed ID: 9067403
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO.
    Clin Cancer Res; 2000 Mar 10; 6(3):874-9. PubMed ID: 10741710
    [Abstract] [Full Text] [Related]

  • 19. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N, Nakamura K, Shitara K.
    Cancer Chemother Pharmacol; 2000 Mar 10; 46 Suppl():S13-7. PubMed ID: 10950141
    [Abstract] [Full Text] [Related]

  • 20. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ.
    Clin Cancer Res; 2003 Nov 01; 9(14):5214-20. PubMed ID: 14614001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.